Padua Prediction Score for VTE Prophylaxis
Predicts risk of VTE in hospitalised medical patients. Score ≥4 defines high-risk patients who benefit from pharmacological thromboprophylaxis. Validated prospectively.
Score interpretation
→ Padua ≥4: High VTE risk (11% without prophylaxis). Pharmacological thromboprophylaxis (adults): LMWH (enoxaparin 40 mg OD or dalteparin 5000 IU OD) or UFH 5000 IU TDS; assess bleeding risk first; continue until mobile or discharge. Children: use a children's formulary.
→ Padua <4: Low VTE risk (0.3% without prophylaxis in Barbar 2010). Pharmacological prophylaxis not routinely recommended; encourage early mobilisation; reassess if clinical status changes.
Interpretation bands for the Padua VTE Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Propranolol (Migraine Prevention) · Beta-Blocker — Migraine Prophylaxis
- Enoxaparin (VTE in Pregnancy) · Low Molecular Weight Heparin (LMWH) — VTE Prophylaxis/Treatment
- Aspirin (Low-Dose — Pre-eclampsia Prevention) · Antiplatelet — Pre-eclampsia Prophylaxis
- Enoxaparin (Orthopaedic VTE Prophylaxis) · Low Molecular Weight Heparin (LMWH)
- Enoxaparin (VTE Prophylaxis — Post-Surgery) · Low Molecular Weight Heparin (LMWH) — VTE Prophylaxis
- Betrixaban (Extended VTE Prophylaxis — Medical Patients) · Oral Factor Xa Inhibitor (DOAC — Extended Duration)
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.